These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2268374)

  • 21. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New method for determination of platelet monoamine oxidase in normal and pathologic subjects].
    Mavelli I; Avigliano L; Bombardieri G; Finazzi Agrò A
    Boll Soc Ital Biol Sper; 1978 Jul; 54(14):1304-8. PubMed ID: 747682
    [No Abstract]   [Full Text] [Related]  

  • 23. Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effects.
    Reynolds GP; Riederer P
    Int Pharmacopsychiatry; 1981; 16(1):30-3. PubMed ID: 7298269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. My love with monoamine oxidase, iron and Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 2006; (71):V-IX. PubMed ID: 17447409
    [No Abstract]   [Full Text] [Related]  

  • 25. Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Park HR; Kim J; Kim T; Jo S; Yeom M; Moon B; Choo IH; Lee J; Lim EJ; Park KD; Min SJ; Nam G; Keum G; Lee CJ; Choo H
    Bioorg Med Chem; 2013 Sep; 21(17):5480-7. PubMed ID: 23810676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
    Zhou G; Miura Y; Shoji H; Yamada S; Matsuishi T
    J Neurol Neurosurg Psychiatry; 2001 Feb; 70(2):229-31. PubMed ID: 11160474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nongenetic factors affecting human platelet monoamine oxidase [proceedings].
    Friedhoff AJ; Miller JC
    Psychopharmacol Bull; 1981 Jan; 17(1):101-3. PubMed ID: 6112772
    [No Abstract]   [Full Text] [Related]  

  • 29. Determination of the absolute concentrations of monoamine oxidase A and B in human tissues.
    O'Carroll AM; Anderson MC; Tobbia I; Phillips JP; Tipton KF
    Biochem Pharmacol; 1989 Mar; 38(6):901-5. PubMed ID: 2495009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models.
    Li L; Zhang CW; Chen GY; Zhu B; Chai C; Xu QH; Tan EK; Zhu Q; Lim KL; Yao SQ
    Nat Commun; 2014; 5():3276. PubMed ID: 24522637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of blood serotonin and benzylamine oxidase to clinical symptoms and prognosis in Parkinson's disease.
    Ishizaki F; Nishikawa S
    Eur Neurol; 1988; 28(5):291-4. PubMed ID: 3224626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mental adaptation to cancer: depression and blood platelet monoamine oxidase activity in breast cancer patients.
    Giraldi T; De Vanna M; Malagoli M; Tuveri G; Sutto K; Schillani G; Grassi L
    Anticancer Res; 2007; 27(3B):1715-9. PubMed ID: 17595803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response.
    Riederer P; Reynolds GP; Jellinger K; Seemann D; Danielczyk W
    Mod Probl Pharmacopsychiatry; 1983; 19():154-61. PubMed ID: 6865963
    [No Abstract]   [Full Text] [Related]  

  • 35. Platelet monoamine oxidase activity in Huntington's chorea.
    Mann J; Chiu E
    J Neurol Neurosurg Psychiatry; 1978 Sep; 41(9):809-12. PubMed ID: 151126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia.
    Wyatt RJ; Murphy DL; Belmaker R; Cohen S; Donnelly CH; Pollin W
    Science; 1973 Mar; 179(4076):916-8. PubMed ID: 4687789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population.
    Varghese M; Pandey M; Samanta A; Gangopadhyay PK; Mohanakumar KP
    J Neurol Sci; 2009 Apr; 279(1-2):39-42. PubMed ID: 19176229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Small-Molecule Probe for Selective Profiling and Imaging of Monoamine Oxidase B Activities in Models of Parkinson's Disease.
    Li L; Zhang CW; Ge J; Qian L; Chai BH; Zhu Q; Lee JS; Lim KL; Yao SQ
    Angew Chem Int Ed Engl; 2015 Sep; 54(37):10821-5. PubMed ID: 26205378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Huleatt PB; Khoo ML; Chua YY; Tan TW; Liew RS; Balogh B; Deme R; Gölöncsér F; Magyar K; Sheela DP; Ho HK; Sperlágh B; Mátyus P; Chai CL
    J Med Chem; 2015 Feb; 58(3):1400-19. PubMed ID: 25627172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
    Youdim MB; Riederer PF
    Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.